415 related articles for article (PubMed ID: 15313457)
41. Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors.
Dodwell D; Wardley A; Johnston S
Breast; 2006 Oct; 15(5):584-94. PubMed ID: 16504510
[TBL] [Abstract][Full Text] [Related]
42. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
Lu Q; Liu Y; Long BJ; Grigoryev D; Gimbel M; Brodie A
Breast Cancer Res Treat; 1999 Sep; 57(2):183-92. PubMed ID: 10598045
[TBL] [Abstract][Full Text] [Related]
43. Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer.
Bundred N
Cancer Invest; 2005; 23(2):173-81. PubMed ID: 15813510
[TBL] [Abstract][Full Text] [Related]
44. Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents.
Vergote I; Abram P
Ann Oncol; 2006 Feb; 17(2):200-4. PubMed ID: 16251200
[TBL] [Abstract][Full Text] [Related]
45. Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.
Esteva FJ; Hortobagyi GN
Breast; 2006 Jun; 15(3):301-12. PubMed ID: 16230014
[TBL] [Abstract][Full Text] [Related]
46. Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.
Gradishar W
Expert Rev Anticancer Ther; 2005 Jun; 5(3):445-53. PubMed ID: 16001952
[TBL] [Abstract][Full Text] [Related]
47. Role of anti-aromatase agents in postmenopausal advanced breast cancer.
Murray R
Cancer Chemother Pharmacol; 2001 Oct; 48(4):259-65. PubMed ID: 11710624
[TBL] [Abstract][Full Text] [Related]
48. Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life.
Harwood KV
Clin J Oncol Nurs; 2004 Dec; 8(6):629-37. PubMed ID: 15637958
[TBL] [Abstract][Full Text] [Related]
49. Time to response: comparison of fulvestrant and oral endocrine agents.
Dodwell D; Pippen J
Clin Breast Cancer; 2006 Aug; 7(3):244-7. PubMed ID: 16942641
[TBL] [Abstract][Full Text] [Related]
50. Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer.
Wiseman LR; Adkins JC
Drugs Aging; 1998 Oct; 13(4):321-32. PubMed ID: 9805213
[TBL] [Abstract][Full Text] [Related]
51. Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model.
Macedo LF; Sabnis GJ; Goloubeva OG; Brodie A
Cancer Res; 2008 May; 68(9):3516-22. PubMed ID: 18451180
[TBL] [Abstract][Full Text] [Related]
52. Fulvestrant in postmenopausal women with advanced breast cancer.
Bross PF; Baird A; Chen G; Jee JM; Lostritto RT; Morse DE; Rosario LA; Williams GM; Yang P; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2003 Oct; 9(12):4309-17. PubMed ID: 14555500
[TBL] [Abstract][Full Text] [Related]
53. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.
Forward DP; Cheung KL; Jackson L; Robertson JF
Br J Cancer; 2004 Feb; 90(3):590-4. PubMed ID: 14760369
[TBL] [Abstract][Full Text] [Related]
54. ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole.
Smollich M; Götte M; Fischgräbe J; Macedo LF; Brodie A; Chen S; Radke I; Kiesel L; Wülfing P
Breast Cancer Res Treat; 2010 Sep; 123(2):345-57. PubMed ID: 19943105
[TBL] [Abstract][Full Text] [Related]
55. Adjuvant endocrine therapies for postmenopausal women with early breast cancer: standards and not.
Dellapasqua S; Castiglione-Gertsch M
Breast; 2005 Dec; 14(6):555-63. PubMed ID: 16188442
[TBL] [Abstract][Full Text] [Related]
56. Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer.
Jones SE; Pippen J
Clin Breast Cancer; 2005 Apr; 6 Suppl 1():S9-14. PubMed ID: 15865850
[TBL] [Abstract][Full Text] [Related]
57. Adjuvant endocrine therapy of perimenopausal and recently postmenopausal women with hormone receptor-positive breast cancer.
Pan K; Chlebowski RT
Clin Breast Cancer; 2014 Jun; 14(3):147-53. PubMed ID: 24503025
[TBL] [Abstract][Full Text] [Related]
58. The effects of aromatase inhibitors and antiestrogens in the nude mouse model.
Lu Q; Yue W; Wang J; Liu Y; Long B; Brodie A
Breast Cancer Res Treat; 1998 Jul; 50(1):63-71. PubMed ID: 9802621
[TBL] [Abstract][Full Text] [Related]
59. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
[TBL] [Abstract][Full Text] [Related]
60. Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer.
Sanford M; Plosker GL
Drugs; 2008; 68(9):1319-40. PubMed ID: 18547136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
